Erste Group Bank Has Pessimistic View of BSX FY2026 Earnings

Boston Scientific Corporation (NYSE:BSX) – Equities researchers at Erste Group Bank decreased their FY2026 earnings per share (EPS) estimates for shares of Boston Scientific in a research note issued to investors on Thursday, June 25th. Erste Group Bank analyst H. Engel now anticipates that the medical equipment provider will earn $3.36 per share for the year, down from their prior forecast of $3.37. The consensus estimate for Boston Scientific’s current full-year earnings is $3.36 per share. Erste Group Bank also issued estimates for Boston Scientific’s FY2027 earnings at $3.71 EPS.

A number of other brokerages also recently weighed in on BSX. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Wells Fargo & Company reiterated an “equal weight” rating and issued a $55.00 target price (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Truist Financial reduced their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, June 4th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a research note on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $83.36.

Boston Scientific Price Performance

Shares of BSX opened at $43.46 on Tuesday. The stock has a market cap of $64.60 billion, a P/E ratio of 18.19, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56. Boston Scientific has a 1 year low of $43.37 and a 1 year high of $109.50. The stock’s 50-day moving average price is $52.47 and its two-hundred day moving average price is $70.63. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after buying an additional 1,436,550 shares during the last quarter. State Street Corp grew its stake in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors grew its stake in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares in the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $2,199,395,000. Finally, Morgan Stanley lifted its position in shares of Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 9,800 shares of company stock worth $554,012 over the last quarter. 0.34% of the stock is currently owned by company insiders.

Boston Scientific declared that its Board of Directors has approved a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.